Outcome Of The Board Meeting Held On 16.05.2026
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tatva Chintan Pharma Chem reported strong audited results for FY2026. Standalone revenue grew 35% to Rs 4,963 million from Rs 3,664 million. Profit before tax surged dramatically to Rs 531.65 million from just Rs 4.61 million in FY2025, while profit after tax jumped to Rs 390.82 million from Rs 1.10 million. Consolidated revenue stood at Rs 5,059 million with PBT of Rs 570.09 million (vs Rs 75.79 million). The Board recommended a final dividend of Rs 2 per share (20%) for shareholder approval at the AGM. New auditor appointments include M/s Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech as Internal Auditor for FY2026-27. Statutory auditors NDJ & Co. issued unmodified opinions on both standalone and consolidated results.
The company showed exceptional turnaround with near 100x improvement in standalone PBT. The recommended dividend signals confidence in sustained profitability. Strong cash generation with positive operating cash flows supports shareholder returns and future growth plans.